Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stella Sarraf
AddedMar 31, 2024
UpdatedMay 31, 2026
Stella Sarraf

Stella Sarraf

Founder & CEO, Spinogenix

CrunchbaseLinkedIn

Stella Sarraf's Career

Spinogenix
Spinogenix

San Diego, CA, US

Founder & CEO· C-Suite · Management
Amydis
Amydis

San Diego, CA, US

Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stella Sarraf's Career

Spinogenix
Spinogenix
Pre-Seed$11.6M82016San Diego, CA, US
Founder & CEO· C-Suite · Management

Similar to Spinogenix

SpheringenicsSpheringenicsAtlanta, GA, USCell Therapiesest. 2007SpheringenicsAtlanta, GA, US · est. 2007

SpherIngenics: Leading biotech firm specializing in innovative cell-based medicinal therapies.

Pre-Seed · $730k4
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Spiral TherapeuticsSpiral TherapeuticsSouth San Francisco, CA, USPharmaceuticalsest. 2016Spiral TherapeuticsSouth San Francisco, CA, US · est. 2016

Spiral Therapeutics: US-based pharmaceutical firm specializing in therapies for inner ear disorders.

Series B · $18.5M11
SynspiraSynspiraFramingham, MA, USBiotechest. 2017SynspiraFramingham, MA, US · est. 2017

Synspira Therapeutics: A clinical-stage biotech firm innovating treatments for cystic fibrosis and rare diseases.

Series B · $25.2M8
Amydis
Amydis
Series A$19.6M412013San Diego, CA, US
Founder & CEO· C-Suite · Management

Similar to Amydis

AdrxAdrxThousand Oaks, CA, USDrug Discoveryest. 2013AdrxThousand Oaks, CA, US · est. 2013

ADRx, Inc.: A California-based biopharmaceutical firm innovating novel drugs for amyloid diseases.

Series A · $24.3M9
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
ADM DiagnosticsADM DiagnosticsNorthbrook, IL, USDiagnostics, Image Analysisest. 2010ADM DiagnosticsNorthbrook, IL, US · est. 2010

ADMdx offers advanced brain image analysis for dementia diagnosis, aiding pharmaceutical trials and patient care.

Seed · $2.9M30
DiamirDiamirMonmouth Junction, NJ, USBiomarkers, Diagnosticsest. 2009DiamirMonmouth Junction, NJ, US · est. 2009

DiamiR: A leading molecular diagnostics firm, innovating early detection solutions for brain health conditions.

Series A · $7.5M30

Stella Sarraf's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Stella Sarraf

Jessica GrossmanJessica GrossmanBoard Member · Daré BioscienceNaveed SalmanNaveed SalmanCEO · CogenicsJ. Kelly GanjeiJ. Kelly GanjeiBoard Member · INmune BioZhenhua WuZhenhua WuCo-Founder · Exegenesis BioWard DetwilerWard DetwilerCo-Founder · SpinTech